Mobile diabetes control system approved for EU

The world’s first mobile-based system for diabetes management, developed by UK company Cellnovo, has received CE Mark approval for sale in the EU.

The innovative Cellnovo system (pictured) combines an insulin patch pump with a touch-screen mobile handset that wirelessly transmits real-time patient data to a web-based portal, enabling patients to keep track of their blood glucose control without needing to keep a diary.

The integration of medication delivery and monitoring technologies, completing the circle of type 1 diabetes control, is strengthened by Cellnovo’s recent agreement with US diabetes monitoring specialist LifeScan.

The successful OneTouch monitoring technology from LifeScan will be incorporated into the Cellnovo system, enabling that a very rapid fingerprick test can be used to generate readings.

The mobile handset is similar to the iPhone, while the patch pump is the smallest and most accurate on the market.

“Cellnovo has created the first insulin pump that combines form with function, essential qualities in a device that patients have to interact with 24/7,” said Dr. Pratik Choudhary, Clinical Lecturer in Diabetes at King’s College London.

Irl B. Hirsch, Professor of Medicine at the University of Washington, Seattle, USA, commented: “Cellnovo has combined advanced mobile and medical technology, which may create a paradigm shift in diabetes care.”

William McKeon, CEO of Cellnovo, described the CE Mark approval as “Cellnovo’s first step in a journey to bring this mobile diabetes management system to the world”.

Based in London, Cellnovo is a mobile healthcare company that specialises in diabetes management.